MedTrace Logo

IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion

NCT06466278 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-10-03

No results posted yet for this study

Summary

This study invastigates the effect of icosapent ethyl in patients with aortic valve stenosis.

Conditions

  • Aortic Valve Stenosis

Interventions

DRUG

Icosapent ethyl

2dd2

DRUG

Placebo

2dd2

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2026-07-01
Completion
2026-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06466278 on ClinicalTrials.gov